title: THE INFLUENCE AND REGULATORY MECHANISM OF Y-BOX BINDING PROTEIN 1 IN OSTEOSARCOMA AND ITS SIGNIFICANCE.
abstract: This study quantified the expression of Y-box binding protein 1 (YB-1) by the immunohistochemical method based on pathological paraffin block specimens of aspiration biopsy from patients with osteosarcoma to explore the influence and regulatory mechanism of YB-1 in osteosarcoma and its significance. Patients were divided into two groups with high and low expressed YB-1, and results showed that 7 cases (13.7%) and 18 cases (26.1%) were in level III, and 44 cases (86.3%) and 51 cases (76.9%) were in level IV respectively, and patients with high YB-1 expression quantity had higher malignant tumor degree (p=0.03). Moreover, the tumor necrosis rate induced by chemotherapy in the two groups were 21 cases (41.2%) and 38 cases (51.8%), respectively. By survival analysis, it was found that a 5-year overall survival rate of patients with high YB-1 expression and low YB-1 expression were 61.2% and 76.6%, respectively (p = 0.054), and 5-year event free survival rates were 52.5% and 72.4%, respectively (p = 0.033). Furthermore, metastasis rate of high YB-1 expression and low YB-1 expression were 41.8% and 22.7%, respectively (p = 0.036), indicating that patients with high YB-1 expression had higher pulmonary metastasis rate. Through further study, we discovered that possibly miR-382 plays a regulatory role in YB-1 gene in osteosarcoma.
authors.affiliation: Oncology Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: W-P
authors.initials: WP
authors.lastname: Zhou
authors.affiliation: Blood Bank Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.affiliation: Geriatrics Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Biological Treatment Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Y-F
authors.initials: YF
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D002648:Child; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D035683:MicroRNAs / Q000502:physiology; D009336:Necrosis; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D012516:Osteosarcoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D012334:RNA, Neoplasm / Q000502:physiology; D016019:Survival Analysis; D051840:Y-Box-Binding Protein 1 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D055815:Young Adult
chemical_list: C555413:MIRN382 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human